Constitutive activation of STAT3 has been observed in most cell lines of NSCLC, and plays a pivotal role in tumor progression and acquired resistance to targeted therapies 13, 24, 44, 45. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.